144 related articles for article (PubMed ID: 27538367)
1. The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.
Smith B; Neff R; Cohn DE; Backes FJ; Suarez AA; Mutch DG; Rush CM; Walker CJ; Goodfellow PJ
Gynecol Oncol; 2016 Nov; 143(2):398-405. PubMed ID: 27538367
[TBL] [Abstract][Full Text] [Related]
2. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
Neff R; Rush CM; Smith B; Backes FJ; Cohn DE; Goodfellow PJ
Int J Cancer; 2018 Dec; 143(11):2955-2961. PubMed ID: 30091462
[TBL] [Abstract][Full Text] [Related]
4. Targeted sequencing with a customized panel to assess histological typing in endometrial carcinoma.
Cuevas D; Valls J; Gatius S; Roman-Canal B; Estaran E; Dorca E; Santacana M; Vaquero M; Eritja N; Velasco A; Matias-Guiu X
Virchows Arch; 2019 May; 474(5):585-598. PubMed ID: 30710169
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
[TBL] [Abstract][Full Text] [Related]
6. Methylation profiles of endometrioid and serous endometrial cancers.
Seeber LM; Zweemer RP; Marchionni L; Massuger LF; Smit VT; van Baal WM; Verheijen RH; van Diest PJ
Endocr Relat Cancer; 2010 Sep; 17(3):663-73. PubMed ID: 20488783
[TBL] [Abstract][Full Text] [Related]
7. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
8. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis.
Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ
Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754
[TBL] [Abstract][Full Text] [Related]
10. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
11. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
Co NN; Iglesias D; Celestino J; Kwan SY; Mok SC; Schmandt R; Lu KH
Cancer; 2014 Nov; 120(22):3457-68. PubMed ID: 25042259
[TBL] [Abstract][Full Text] [Related]
12. Expression of type 2 orexin receptor in human endometrium and its epigenetic silencing in endometrial cancer.
Dehan P; Canon C; Trooskens G; Rehli M; Munaut C; Van Criekinge W; Delvenne P
J Clin Endocrinol Metab; 2013 Apr; 98(4):1549-57. PubMed ID: 23482607
[TBL] [Abstract][Full Text] [Related]
13. Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.
Walker CJ; Miranda MA; O'Hern MJ; McElroy JP; Coombes KR; Bundschuh R; Cohn DE; Mutch DG; Goodfellow PJ
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26330387
[TBL] [Abstract][Full Text] [Related]
14. Protocadherin 10 inhibits cell proliferation and induces apoptosis via regulation of DEP domain containing 1 in endometrial endometrioid carcinoma.
Yang Y; Jiang Y; Jiang M; Zhang J; Yang B; She Y; Wang W; Deng Y; Ye Y
Exp Mol Pathol; 2016 Apr; 100(2):344-52. PubMed ID: 26970279
[TBL] [Abstract][Full Text] [Related]
15. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
16. The FOXO1-miR27 tandem regulates myometrial invasion in endometrioid endometrial adenocarcinoma.
Mozos A; Catasús L; D'Angelo E; Serrano E; Espinosa I; Ferrer I; Pons C; Prat J
Hum Pathol; 2014 May; 45(5):942-51. PubMed ID: 24746199
[TBL] [Abstract][Full Text] [Related]
17. Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers.
Zighelboim I; Goodfellow PJ; Schmidt AP; Walls KC; Mallon MA; Mutch DG; Yan PS; Huang TH; Powell MA
Clin Cancer Res; 2007 May; 13(10):2882-9. PubMed ID: 17504987
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1.
Xu YY; Wu HJ; Ma HD; Xu LP; Huo Y; Yin LR
FEBS J; 2013 Aug; 280(16):3768-79. PubMed ID: 23731275
[TBL] [Abstract][Full Text] [Related]
19. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
[TBL] [Abstract][Full Text] [Related]
20. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
